Company intelligence / Profile preview
ADC Therapeutics
Epalinges, Vaud, Switzerlandadctherapeutics.com ↗
- Ownership
- Public · ADCT
- Development stage
- Other
01
Overview
ADC Therapeutics has achieved FDA accelerated approval and EU conditional approval for ZYNLONTA® in relapsed/refractory DLBCL after two or more prior therapies. Clinical data show significant single-agent activity across a broad population of patients with aggressive lymphomas. Other pipeline assets are advancing through early to late-stage clinical trials targeting both hematological cancers and solid tumors.
- Therapeutic areas
- HematologyOncology
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)Proprietary payloads (e.g., pyrrolobenzodiazepine [PBD], exatecan-based payloads)
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Collaborations with academic centers such as MD Anderson Cancer Center for clinical trials
04
Financials
- Market cap
- $209.4M
- Total revenue
- $81.4M
- Enterprise value
- $408.3M
Beyond the preview
Go deeper on ADC Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC Therapeutics.